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3Abstract27
Lactic acid bacteria (LAB) produce a wide variety of antimicrobial peptides28
(bacteriocins) which contribute to the safety and preservation of fermented foods.29
This review discusses strategies that have or could be employed to further enhance the30
commercial application of bacteriocins and/or bacteriocin-producing LAB for food31
use.32
4Introduction33
Bacteriocin production is a desirable trait among LAB from the perspective of34
controlling microbial populations in fermented foods in order to extend product shelf-35
life and safety. Bacteriocins produced by LAB are a diverse group of ribosomally-36
synthesized antimicrobial peptides which may be divided into two main groups i.e.37
class I peptides, which contain post-translational modifications, and class II, or38
unmodified, peptides [1]. Broad spectrum bacteriocins, such as nisin (class I), inhibit39
Gram positive food-borne pathogens and spoilage microbes and, when combined with40
additional hurdles, Gram negative targets [2]. Narrow spectrum bacteriocins can also41
be of value, for example, lactococcin A (class II) has a lytic effect on sensitive42
lactococci which, through the release of key enzymes, can accelerate cheese ripening43
and enhance the development of important organoleptic properties [3]. Bacteriocins44
may be introduced into a food via in situ production by bacterial starter or adjunct45
strains in fermented foods, by the addition of purified or semi-purified preparations46
(e.g. nisin containing powders such as Nisaplin) or as an ingredient based on a47
fermentate of a bacteriocin producing strain (such as ALTA2431 which contains48
pediocin PA1). However, the commercial application of specific bacteriocins can be49
hindered by low or inconsistent production levels, high production costs, a non-ideal50
antimicrobial spectrum and potency, the risk of the emergence of resistance and the51
poor/lack of growth of some producing strains in particular foods. This review52
discusses some of the strategies developed to overcome such limiting factors.53
54
Influence of growth parameters55
Many studies have been dedicated to optimising bacteriocin production by56
manipulating growth media composition, temperature or pH [4-6]. Investigations of57
5alternative carbon, nitrogen and mineral sources have successfully led to increased58
bacteriocin yields or more cost effective production [7-9]. Another strategy has been59
the inclusion of additional stimuli. In the case of Lactobacillus plantarum NC8, a60
starter strain used in Spanish-style green olive fermentations, and Leuconostoc61
citreum GJ7, a kimchi isolate, this occurs through the addition of specific adjunct62
strains that induce bacteriocin-production [10,11].63
64
Use of conjugation to transfer a bacteriocin producing phenotype65
Conjugation provides a natural mechanism by which genes can be transferred from66
one LAB to another while maintaining the food grade status of the recipient strain. As67
many bacteriocins are plasmid encoded, this approach has been widely exploited to68
disseminate bacteriocin-producing phenotypes. This is exemplified by the generation69
of over 30 food grade Lactococcus strains that produce the broad spectrum two-70
component class I bacteriocin lacticin 3147 through the transfer of pMRC01, a71
conjugative plasmid which contains the corresponding genetic determinants [12].72
Although the presence of pMRC01 may impose an additional metabolic burden on73
LAB, which can increase cell permeability and autolysis, it does not impact on the74
acidification capacity of the strain [13]. In addition to the transfer of the bacteriocin75
producing phenotype itself, bacteriocin production (and the associated bacteriocin76
immunity phenotype) can also serve as a food grade selectable marker when77
transferring additional, plasmid-linked, industrially relevant traits. Indeed, while78
conjugal transfer of pMRC01 to the lacticin 481 producing host Lactococcus lactis79
DPC5552 generated a co-producing transconjugant which exhibited synergistic80
activity [14], both bacteriocins have served as effective food grade selectable markers81
for the transfer of bacteriophage resistance phenotypes to important commercial dairy82
6starter strains, thereby reducing phage sensitivity [15,16]. It should also be noted that83
the conjugal transfer of plasmids encoding other traits, such as lactose utilisation and84
protease activity, can facilitate increased bacteriocin production by adapting the85
producing strain for better growth in food environments. Indeed, Garcia-Parra et al,86
reported a 40-fold increase in nisin production by one such transconjugant in milk87
[17]. The genetic determinants for nisin are also located on a conjugative transposon88
enabling its food-grade transfer to other LAB [18], and the nisin resistance phenotype89
has also been widely exploited as a selection marker for food grade improvement of90
starter strains [19,20].91
Strategies have also been adapted to mobilize bacteriocin-encoding non-conjugative92
plasmids for the improvement of starter strains in a food grade manner [21,22]. Such93
plasmids, unable to mediate their own transfer, require the sequence of the origin of94
transfer (oriT) and mobA gene, while the genes encoding other conjugal functions are95
supplied in trans from a conjugative plasmid or sex factor. L. lactis IFPL35996
transconjugants generated in this way to harbour the lacticin 3147-encoding non-97
conjugative plasmid pBaC105 successfully accelerated proteolysis and development98
of sensory characteristics of semi-hard goat cheese [21].99
Aside from the ‘donor’ strain from which these plasmids and transposons are being100
mobilised, it should also be noted the genetic composition of recipient strains can101
ultimately influence the success of the conjugative approach. Indeed, L. lactis subsp102
lactis IL1403 is frequently selected for studies of lactococcin A (LcnA; class II)-type103
bacteriocins as this strain contains chromosomal analogues of the genes involved in104
LcnA secretion and maturation (i.e. lcnC and lcnD). Indeed, the extent of bacteriocin105
production by this strain following the conjugal transfer of pS140, a plasmid106
harbouring the genetic determinants for a lactococcin A-like bacteriocin, was greater107
7than that of other lactococcal transconjugants, presumably as a consequence of the108
additional copies of lcnCD already present [23].109
110
Subcloning and expression of bacteriocin genes or gene clusters111
Subcloning and expression of bacteriocin genes and gene clusters has also been112
applied as a means of conferring a bacteriocin positive phenotype on LAB strains or113
to facilitate over-production in a strain that is already a natural bacteriocin producer.114
Indeed, a particularly effective strategy employed for the overproduction of various115
class I bacteriocins has been the introduction of additional copies of biosynthesis-116
associated genes to an existing bacteriocin-producing host. This has led to greater117
yields of nisin [24,25] and of the individual lacticin 3147 component peptides, Ltn118
and Ltn, as well as improved yields of bioengineered lacticin 3147 variants [26].119
Such studies have also established that the introduction of additional copies of120
immunity (self-protection) genes can be important to overcome self-toxicity-121
associated limitations when overproducing these peptides.122
The heterologous production of class II bacteriocins by LAB is dependant on several123
factors such as the host strain, the expression and secretion systems employed,124
plasmid stability and copy number and the presence of the cognate bacteriocin125
immunity genes. While expression systems employing constitutive promoters and126
inducible promoters (such as the nisin-inducible promoter, (PnisA, of the NIsin127
Controlled gene Expression (NICE) system [27]) have both been highly exploited,128
inducible systems have in general been more successful. Regardless of promoter, the129
strategies involved have varied from cloning of the entire, intact bacteriocin130
biosynthetic gene cluster [28,29] to the creation of gene fusions (to facilitate efficient131
bacteriocin transport) through the exploitation of bacteriocin leader or secretion132
8signals [30-37]. Yeast based platforms have also shown considerable promise. These133
may be useful for the large-scale production of bacteriocins or for yeast based134
fermentations [38-41].135
Although these recombination techniques can facilitate increased levels of bacteriocin136
production and activity, and the construction of improved multi-bacteriocin producing137
strains, they remain genetically modified organisms (GMO) which may limit their138
application in the wider Food Industry.139
140
Bioengineering of bacteriocin peptides141
There have been a number of instances in which bioengineering of bacteriocin142
structural genes (through manipulation of the gene in a natural producer or in a strain143
which produces the bacteriocin heterologously) has been employed with a view to144
expanding or altering the associated antimicrobial spectrum. This strategy initially145
evolved from a desire to gain a better appreciation of the importance of specific146
residues or domains within these peptides, i.e. to assess the negative consequences of147
mutating these regions. However, this approach has evolved such that strains with148
greater antimicrobial potency have resulted which can potentially provide for the149
better control of spoilage or pathogenic microbes.150
Bioengineering-based strategies were first applied to LAB producers of class I151
bacteriocins, with the targeting of nisin [42-44] being of greatest relevance to this152
review. Subsequent, manipulations of nisin were crucial with respect to elucidating153
the mechanism of action of the peptide [45-48]. From these, and more recent studies,154
some bioengineered nisins are notable by virtue of possessing enhanced antimicrobial155
activity against at least one, albeit non-pathogenic, Gram positive target [49-52].156
Other bioengineered derivatives of nisin have been identified which more effectively157
9inhibit one or more pathogenic targets. The majority of these are derivatives in which158
residues within a central, 3-amino acid, stretch known as the ‘hinge’ region have been159
altered. Here, examples include nisins N20K and M21K [53], nisin M21V [54-56],160
nisin K22T (figure 1), [55] and nisin N20P [54]. Recently, nisin peptides in which161
serine 29 has been altered have drawn attention by virtue of exhibiting enhanced162
activity against both Gram positive and Gram negative pathogens [57]. It should also163
be noted that there have also been instances in which the nisin structural gene has164
been altered to facilitate the production of other natural variants of nisin (nisin Z, F165
and Q; [58]) or in a manner that has resulted in peptides which exhibit enhanced166
diffusion through complex matrices [59]. Other class I bacteriocin producing LAB,167
i.e. the producers of lacticin 3147 and lacticin 481, have also been the focus of168
bioengineering-based strategies. In these cases, the outcomes have been of greater169
importance from a fundamental science, rather than applied, perspective [60-66], with170
only one example of a partial enhancement having been described to date [64]. Aside171
from the lantibiotics, as derivatives of the unmodified class II bacteriocins can be172
generated both synthetically [67,68] or through heterologous expression [69-77] with173
relative ease, there are relatively few examples of instances in which LAB producers174
of the class II bacteriocins have themselves been engineered. However, the potential175
exists to reconstitute production of some of the more interesting derivatives in the176
original host strain should the need or desire arise.177
It is important to note that while all bioengineering based strategies are valid if the178
aim is to create bacteriocins for fundamental analyses or applications by the179
pharmaceutical industry, the application of bioengineered bacteriocin peptides as food180
preservatives is a bigger obstacle in some jurisdictions. Indeed, many of the strategies181
employed to produce the engineered bacteriocins described above involve approaches182
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that result in the producer needing to be described as a GMO. However, alternatives183
exist. Indeed, self cloning of non-pathogenic microorganisms is not considered to lead184
to a GMO as long as containment of the organism is guaranteed (directive185
90/219/EC). Accordingly, the temporary introduction of plasmids, the deletion of186
specific DNA sequences, or introduction of DNA from another micro-organism187
belonging to the same species fall within the definition of self-cloning. Thus, subtle188
alterations to bacteriocin structural genes (such as the changing of single codons)189
made using food grade strategies [78] fall outside the remit of the Contained Use190
legislation and therefore are not regulated as GMOs.191
192
Conclusions193
There are various methods available to improve the bacteriocin-mediated protection194
provided by food grade LAB. While genetic manipulation by recombinant and195
bioengineering based approaches offer great promise, only strains which have been196
modified through non-recombinant approaches can be directly added to food. In197
addition to the further improvement of existing strains, advances with respect to high198
throughput screening strategies are likely to result in the identification of novel199
antimicrobials with considerable potential for food applications. Few naturally200
occurring multi-bacteriocin producing LAB have been identified [79-83]. However,201
ongoing developments in traditional microbiological, mass spectrometric, molecular202
and bioinformatic screening techniques [84,85] has led to the isolation [86-94] and203
characterisation of several novel bacteriocins [95-98] reported this year alone which204
may find applications in food. Regardless of the strain and bacteriocin in question, it205
is fair to say that the application of bacteriocin producing LAB, alone or in206
combination with additional antimicrobial hurdles [2], continues to be a relatively207
11
underutilised strategy that, through various enhancements such as those described208
here, could be more widely applied by the food industry.209
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Figure 1. Enhanced activity of bioengineered L. lactis producing nisin derivatives569
mutated within the ‘hinge’ region, K22T and K22S, against Streptococcus agalactiae570
ATCC13813 as compared with the respective nisin A producing controls (as adapted571
from Field et al., (2008)).572
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